Patients characteristics
high‐dose, transplantation failure
ONCOLOGY, DISEASE PROGRESSION
Fifty‐six patients with evaluable efficacy were included in this study, most of whom were unable to undergo high‐dose chemotherapy or hematopoietic stem cell transplantation due to disease progression, comorbidities, poor response to previous treatments, or previous transplantation failure. There were no significant differences in patient characteristics between the decitabine‐RDHAP group (35 cases) and the RDHAP group (21 cases). Overall, 54% of the patients (Patient characteristics
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase; RDHAP, rituximab, cisplatin, cytarabine, dexamethasone; β2‐MG, β2‐microglobulin.